

ASX RELEASE

15 August 2016

Appointment of Chief Operating Officer

MMJ PhytoTech Limited (ASX: MMJ) (“**MMJ**” or “**the Company**”) is pleased to advise that Catherine Harvey has been appointed as Chief Operations Officer, effective 1 September 2016.

In the role of Chief Operations Officer, Catherine will play a significant role in overseeing the daily operations of MMJ’s key business divisions, with a focus on the execution of key international growth objectives. Catherine will be based in Sydney and will work closely with MMJ’s senior management team to design and deliver MMJ’s commercial and regulatory strategy, with a focus on the Australian market, but also overseeing MMJ’s international operations.

Catherine is a highly experienced pharmaceutical industry executive, with an extensive corporate background, having worked for multiple pharmaceutical organisations both domestically and overseas. Most recently, Catherine held executive leadership positions including Director of Business Development and Corporate Affairs at Mundipharma Pty Limited and Business Development Manager at Norwegian Pharmaceutical company, Nycomed.

Throughout her career to date, Catherine has established a strong track record in the implementation of successful commercialisation strategies and strategic planning at senior management level.

MMJ’s Managing Director, Andreas Gedeon, commented on the appointment, “We are very pleased to be welcoming someone of Catherine’s calibre to the management team, during this exciting period in our evolution as a leading vertically integrated medical cannabis business.

Catherine’s extensive pharmaceutical industry experience, in particular her ability to drive commercial strategies and sales growth, will be a tremendous addition to the team and will provide MMJ with the requisite bench strength to build upon our robust foundations as we look to capitalise on a number of near-term growth opportunities.”

As part of Catherine’s remuneration package, the Company has agreed to grant her 3,000,000 unlisted options with an expiry date of 4 years from the date of issue and an exercise price equal to the 5 day VWAP of the underlying MMJ shares traded on the ASX immediately prior to the commencement of her employment on 1 September 2016. The options will vest in equal thirds every 12 months, subject to Catherine’s ongoing employment with the Company.

– ENDS –

ASX RELEASE

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.